Tempest Therapeutics (TPST) Operating Expenses (2012 - 2026)
Tempest Therapeutics (TPST) posted Operating Expenses of $4.1 million for Q4 2025, up 13.34% sequentially from $3.6 million in Q3 2025, and down 70.71% YoY from $13.9 million in Q4 2024.
Tempest Therapeutics (TPST) Operating Expenses (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Operating Expenses for 14 years, with the latest figure at $4.1 million in Q4 2025.
- Quarterly Operating Expenses fell 70.71% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.6 million (down 36.76% YoY) and the FY2025 annual result came in at $26.6 million, down 36.77% from the prior year.
- Operating Expenses climbed to $4.1 million in Q4 2025 per TPST's latest filing, from $3.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $13.9 million in Q4 2024 and troughed at $3.6 million in Q3 2025.
- A 5-year average of $8.0 million and a median of $7.9 million in 2021 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 85.23% in 2024, then sank 70.71% in 2025.
- Over 5 years, Operating Expenses stood at $7.3 million in 2021, then gained by 21.75% to $8.9 million in 2022, then dropped by 15.89% to $7.5 million in 2023, then surged by 85.23% to $13.9 million in 2024, then sank by 70.71% to $4.1 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $4.1 million, $3.6 million, and $8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.25 Mn |
| Dec 31, 2025 | 4.08 Mn |
| Sep 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 7.97 Mn |
| Mar 31, 2025 | 10.94 Mn |
| Dec 31, 2024 | 13.92 Mn |
| Sep 30, 2024 | 10.55 Mn |
| Jun 30, 2024 | 9.58 Mn |
| Mar 31, 2024 | 7.97 Mn |
| Dec 31, 2023 | 7.51 Mn |
| Sep 30, 2023 | 6.59 Mn |
| Jun 30, 2023 | 7.47 Mn |
| Mar 31, 2023 | 7.58 Mn |
| Dec 31, 2022 | 8.93 Mn |
| Sep 30, 2022 | 8.77 Mn |
| Jun 30, 2022 | 8.77 Mn |
| Mar 31, 2022 | 8.16 Mn |
| Dec 31, 2021 | 7.34 Mn |
| Sep 30, 2021 | 7.74 Mn |
| Jun 30, 2021 | 6.79 Mn |